Clinical trials
Triple Negative Breast Neoplasms trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 6 |
| Active, not recruiting | 5 |
| Terminated | 5 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 5 |
| Hoffmann-La Roche | 3 |
| Amgen | 2 |
| Bristol-Myers Squibb | 2 |
| Gilead Sciences | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Swiss Cancer Institute | 2 |
| Array Biopharma, now a wholly owned subsidiary of Pfizer | 1 |
| Bayer | 1 |
| Centre Hospitalier Universitaire Vaudois | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 26 |
| Breast Neoplasms | 7 |
| Pancreatic Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Colorectal Neoplasms | 4 |
| Melanoma | 3 |
| Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| Carcinoma, Ovarian Epithelial | 2 |
| Carcinoma, Renal Cell | 2 |
Trials
Showing 51 to 26 of 26. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.